Elevance Health (ELV) Price to Sales (2009 - 2026)

Elevance Health (ELV) has reported Price to Sales for 18 consecutive years, with 1.66 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 5.43% year-over-year to 1.66 in Q2 2026; TTM through Jun 2026 was 0.42, a 9.78% decrease from a year earlier, with the FY2025 full-year figure at 0.39, down 18.04% from the prior year.
• Price to Sales was 1.66 for Q2 2026 at Elevance Health, up from 1.27 in the prior quarter.
• Over five years, Price to Sales peaked at 3.11 in Q1 2022 and troughed at 1.27 in Q1 2026.
• A 5-year average of 2.32 and a median of 2.49 in 2023 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales increased 19.33% in 2024 and plunged 47.09% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 3.06 in 2022, then slipped by 15.7% to 2.58 in 2023, then retreated by 28.34% to 1.85 in 2024, then declined by 15.78% to 1.56 in 2025, then advanced by 6.82% to 1.66 in 2026.
• The last three Price to Sales figures came in at 1.66 (Q2 2026), 1.27 (Q1 2026), and 1.56 (Q4 2025), per Business Quant data.